Synthesis and cytotoxic activity of novel amidine analogues of bis(2-chloroethyl)amine

Archiv der Pharmazie

Volumn 342, Issue 8, 2009, Pages 484-490

  Bielawski, Krzysztof ^a   Bielawska, Anna ^a   Poplawska, Bozena ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Alkylating agents; Amidines; Cytotoxicity; DNA binding ; Topoisomerase II

Indexed keywords

AMIDINE; CHLORAMBUCIL; CONGOCIDINE; CYTOTOXIC AGENT; DISTAMYCIN A; GYRASE INHIBITOR; N [3 [4 BIS(2 CHLOROETHYL)AMINOPHENYL]PROPYL] 5 (4 AMIDINOPHENYL) 2 FURANCARBOXAMIDE; N [3 [4 BIS(2 CHLOROETHYL)AMINOPHENYL]PROPYL] 5 [4 (3,4,5,6 TETRAHYDRO 1H PYRIMIDINE 2 YL)PHENYL] 2 FURANCARBOXAMIDE; N [3 [4 BIS(2 CHLOROETHYL)AMINOPHENYL]PROPYL] 5 [4 (4,5 DIHYDRO 1H IMIDAZOL 2 YL)PHENYL] 2 FURANCARBOXAMIDE; N [3 [4 BIS(2 CHLOROETHYL)AMINOPHENYL]PROPYL] 5 [4 (N CYCLOPENTYLAMIDINO)PHENYL] 2 FURANCARBOXAMIDE; N [3 [4 BIS(2 CHLOROETHYL)AMINOPHENYL]PROPYL] 5 [4 (N CYCLOPROPYLAMIDINO)PHENYL] 2 FURANCARBOXAMIDE; N [3 [4 BIS(2 CHLOROETHYL)AMINOPHENYL]PROPYL] 5 [4 (N ISOPROPYLAMIDINO)PHENYL] 2 FURANCARBOXAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL LINE; CELL STRAIN MCF 7; CELL VIABILITY; CHEMICAL BOND; CONTROLLED STUDY; CYTOTOXICITY; DNA SYNTHESIS; DRUG DNA BINDING; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

AMIDINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DNA; DNA TOPOISOMERASES, TYPE II; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MECHLORETHAMINE; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE;

EID: 68249126109     PISSN: 03656233     EISSN: 15214184     Source Type: Journal    
DOI: 10.1002/ardp.200800231     Document Type: Article

References (25)

1. P. B. Farmer, Pharmacol. Therap. 1987, 35, 301-358.
2. C. S. Morrow, P. K. Smitherman, S. K. Diah, E. Schneider, A. J. Townsend, J. Biol. Chem. 1998, 273, 20114-20120.
3. P. K. Smitherman, A. J. Townsend, T. E. Kute, C. S. Morrow, J. Pharmacol. Exp. Ther. 2004, 308, 260-267.
4. K. Bielawski, A. Bielawska, Chem. Med. Chem. 2008, 3, 536-542.
5. W. A. Denny, Curr. Med. Chem. 2001, 8, 533-544.
6. P. G. Baraldi, D. Preti, F. Fruttarolo, M. Tabrizi, R. Romagnoli, Bioorg. Med. Chem. 2007, 15, 17-35.
7. S. M. Nelson, L. R. Ferguson, W. A. Denny, Mutat. Res. 2007, 623, 24-40.
8. S. Neidle, Nat. Prod. Rep. 2001, 18, 291-309.
9. U. Pindur, M. Jansen, T. Lemster, Curr. Med. Chem. 2005, 12, 2805-2847.
10. A. Bielawska, K. Bielawski, S. Wolczynski, T. Anchim, Arch. Pharm. Pharm. Med. Chem. 2003, 336, 293-299.
11. A. Bielawska, K. Bielawski, A. Muszynska, Il Farmaco 2004, 59, 111-117.
12. K. Bielawski, A. Bielawska, K. Sosnowska, W. Miltyk, et al., Biochem. Pharm. 2006, 72, 320-331.
13. A. Bielawska, K. Bielawski, T. Anchim, Arch. Pharm. Chem. Life Sci. 2007, 340, 251-257.
14. B. Nguyen, Ch. Tardy, Ch. Bailly, P. Colson, et al., Biopolymers 2002, 63, 281-297.
15. A. Bielawska, K. Bielawski, S. Wolczynski, Pharmazie 2001, 5, 428-429.
16. K. Bielawski, A. Bielawska, S. Wolczynski, Arch. Pharm. Pharm. Med. Chem. 2001, 334, 235-240.
17. J. C. Marquis, S. M. Hillier, A. N. Dinaut, D. Rodrigues, et al., Chem. Biol. 2005, 12, 779-787.
18. J. Carmichael, W. Degraff, A. Gazdar, J. Minna, J. Mitchell, Cancer Res. 1987, 47, 936-942.
19. A. R. Morgan, J. S. Lee, D. F. Pulleyblank, N. L. Murray, D. H. Evans, Nucl. Acid. Res. 1979, 7, 547-569.
20. F. Debart, C. Periguad, D. Gosselin, D. Mrani, et al., J. Med. Chem. 1989, 32, 1074-1083.
21. J. W. Lown, Acc. Chem. Res. 1982, 15, 381-387.
22. W. D. Wilson, B. Nguyen, F. A. Tanious, A. Mathis, et al., Curr. Med. Chem. 2005, 5, 389-408.
23. J. C. Wang, Nat. Rev. Mol. Cell. Biol. 2002, 3, 430-440.
24. J. J. Champoux, Annu. Rev. Biochem. 2001, 70, 369-413.
25. A. K. McClendon, N. Osheroff , Mutat. Res. 2007, 623, 83-97.